Phase II study of ET-743 in patients with translocation-related sarcomas

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221808

Enrollment

Registered

2012-05-31

Start date

2012-05-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with malignant soft tissue sarcomas of histological types that have been reported to carry chromosomal translocations

Interventions

investigational material(s) Generic name etc : ET-743 INN of investigational material : trabectedin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Any of TRS histopathologically confirmed at the study site - Unresponsiveness or intolerability to the standard chemotherapy regimens - Other

Exclusion criteria

Exclusion criteria: - Severe concurrent disease - Other

Design outcomes

Primary

Measure	Time frame
Progression free survival RECIST ver.1.1	—

Secondary

Measure	Time frame
Overall response rate, Disease control rate, Safety, Overall survival, PK parameter RECIST ver.1.1, CTCAE ver.4.03	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026